FCGR3A and neoplasm: In our study, we showed that two novel [CD20×NKG2D] bibodies enhanced the ADCC of mAbs targeting CD19 or CD38 on the same tumor cells, thus, demonstrating the synergy of the NKG2D and FcγRIIIA mediated dual NK cell activation and the dual targeting of the CD20+/CD19+ or CD20+/CD38+ tumor cell lines.